Autoantibodies to a 140‐kd protein in juvenile dermatomyositis are associated with calcinosis

Abstract

Objective The identification of novel autoantibodies in juvenile dermatomyositis (DM) may have etiologic and clinical implications. The aim of this study was to describe autoantibodies to a 140‐kd protein in children recruited to the Juvenile DM National Registry and Repository for UK and Ireland. Methods Clinical data and sera were collected from children with juvenile myositis. Sera that recognized a 140‐kd protein by immunoprecipitation were identified. The identity of the p140 autoantigen was investigated by immunoprecipitation/immunodepletion, using commercial monoclonal antibodies to NXP‐2, reference anti‐p140, and anti‐p155/140, the other autoantibody recently described in juvenile DM. DNA samples from 100 Caucasian children with myositis were genotyped for HLA class II haplotype associations and compared with those from 864 randomly selected UK Caucasian control subjects. Results Sera from 37 (23%) of 162 patients with juvenile myositis were positive for anti‐p140 autoantibodies, which were detected exclusively in patients with juvenile DM and not in patients with juvenile DM–overlap syndrome or control subjects. No anti‐p140 antibody–positive patients were positive for other recognized autoantibodies. Immunodepletion suggested that the identity of p140 was consistent with NXP‐2 (the previously identified MJ autoantigen). In children with anti‐p140 antibodies, the association with calcinosis was significant compared with the rest of the cohort (corrected P < 0.005, odds ratio 7.0, 95% confidence interval 3.0–16.1). The clinical features of patients with anti‐p140 autoantibodies were different from those of children with anti‐p155/140 autoantibodies. The presence of HLA–DRB1*08 was a possible risk factor for anti‐p140 autoantibody positivity. Conclusion This study has established that anti‐p140 autoantibodies represent a major autoantibody subset in juvenile DM. This specificity may identify a further immunogenetic and clinical phenotype within the juvenile myositis spectrum that includes an association with calcinosis.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 34

1. 1.

   Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, for the NIAMS Juvenile DM Registry Physician Referral Group, et al. US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 2003;49:300-5.

   Not in our library10.1002/art.11122

2. 2.

   Oddis CV, Conte CG, Steen VD, Medsger TA. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol. 1990;17:1329-34.

   Not in our library

3. 3.

   Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol. 1995;34:732-6.

   Not in our library10.1093/rheumatology/34.8.732

4. 4.

   Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum. 2000;43:541-9.

   Not in our library10.1002/1529-0131(200003)43:3<541::aid-anr9>3.0.co;2-t

5. 5.

   Ramanan AV, Feldman BM. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am. 2002;28:833-57.

   Not in our library10.1016/s0889-857x(02)00024-8

6. 6.

   McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson JE, Murray KJ, on behalf of the Juvenile Dermatomyositis Research Group, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland): clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford). 2006;45:1255-60.

   Not in our library10.1093/rheumatology/kel099

7. 7.

   Pilkington CA, Wedderburn LR. Paediatric idiopathic inflammatory muscle disease: recognition and management. Drugs. 2005;65:1355-65.

   Not in our library10.2165/00003495-200565100-00004

8. 8.

   Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991;70:360-74.

   Not in our library10.1097/00005792-199111000-00002

9. 9.

   Targoff IN. Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol. 2000;12:475-81.

   Not in our library10.1097/00002281-200011000-00001

10. 10.

    Targoff IN. Myositis specific autoantibodies. Curr Rheumatol Rep. 2006;8:196-203.

    Not in our library10.1007/s11926-996-0025-3

11. 11.

    Yoshifuji H, Fujii T, Kobayashi S, Imura Y, Fujita Y, Kawabata D, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity. 2006;39:233-41.

    Not in our library10.1080/08916930600622884

12. 12.

    Wedderburn LR, McHugh NJ, Chinoy H, Cooper RG, Salway F, Ollier WE, et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford). 2007;46:1786-91.

    Not in our library10.1093/rheumatology/kem265

13. 13.

    Feldman BM, Reichlin M, Laxer RM, Targoff IN, Stein LD, Silverman ED. Clinical significance of specific autoantibodies in juvenile dermatomyositis. J Rheumatol. 1996;23:1794-7.

    Not in our library

14. 14.

    Rider LG, Miller FW, Targoff IN, Sherry DD, Samayoa E, Lindahl M, et al. A broadened spectrum of juvenile myositis: myositis-specific autoantibodies in children. Arthritis Rheum. 1994;37:1534-8.

    Not in our library10.1002/art.1780371019

15. 15.

    Rouster-Stevens KA, Pachman LM. Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J Rheumatol. 2008;35:927-9.

    Not in our library

16. 16.

    Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, for the Childhood Myositis Heterogeneity and International Myositis Collaborative Study Group, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54:3682-9.

    Not in our library10.1002/art.22164

17. 17.

    Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, Chinoy H, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford). 2008;47:324-8.

    Not in our library10.1093/rheumatology/kem359

18. 18.

    Oddis CV, Fertig N, Goel A, Espada G, Confalone Gregorian M, Maldonado Cocco JA, et al. Clinical and serological characterization of the anti-MJ antibody in childhood myositis. Arthritis Rheum. 1997;40:S139.

    Not in our library

19. 19.

    Targoff IN, Trieu EP, Levy-Neto M, Fertig N, Oddis CV. Sera with autoantibodies to the MJ antigen react with NXP2. Arthritis Rheum. 2007;56:S787.

    Not in our library

20. 20.

    Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344-7.

    Not in our library10.1056/nejm197502132920706

21. 21.

    Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403-7.

    Not in our library10.1056/nejm197502202920807

22. 22.

    Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini EH, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum. 1999;42:2213-9.

    Not in our library10.1002/1529-0131(199910)42:10<2213::aid-anr25>3.0.co;2-8

23. 23.

    Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford). 2007;46:1005-8.

    Not in our library10.1093/rheumatology/kem045

24. 24.

    Chinoy H, Salway F, Fertig N, Shephard N, Tait BD, Thomson W, UK Adult Onset Myositis Immunogenetic Collaboration (AOMIC), et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther. 2006;8:R13.

    Not in our library10.1186/ar1862

25. 25.

    Doherty DG, Vaughan RW, Donaldson PT, Mowat AP. HLA DQA, DQB, and DRB genotyping by oligonucleotide analysis: distribution of alleles and haplotypes in British caucasoids. Hum Immunol. 1992;34:53-63.

    Not in our library10.1016/0198-8859(92)90085-2

26. 26.

    Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1994;37:1761-9.

    Not in our library10.1002/art.1780371209

27. 27.

    Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol. 2002;47:505-11.

    Not in our library10.1067/mjd.2002.122196

28. 28.

    Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM, et al. TNFα-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor α, disease duration, and pathologic calcifications. Arthritis Rheum. 2000;43:2368-77.

    Not in our library10.1002/1529-0131(200010)43:10<2368::aid-anr26>3.0.co;2-8

29. 29.

    Pachman LM, Veis A, Stock S, Abbott K, Vicari F, Patel P, et al. Composition of calcifications in children with juvenile dermatomyositis: association with chronic cutaneous inflammation. Arthritis Rheum. 2006;54:3345-50.

    Not in our library10.1002/art.22158

30. 30.

    Kimura Y, Sakai F, Nakano O, Kisaki O, Sugimoto H, Sawamura T, et al. The newly identified human nuclear protein NXP-2 possesses three distinct domains, the nuclear matrix-binding, RNA-binding, and coiled-coil domains. J Biol Chem. 2002;277:20611-7.

    Not in our library10.1074/jbc.m201440200

31. 31.

    Targoff IN, Trieu EP, Levy-Neto M, Prasertsuntarasai T, Miller FW. Autoantibodies to transcriptional intermediary factor 1-gamma (TIF1-g) in dermatomyositis. Arthritis Rheum. 2006;54:S518.

    Not in our library

32. 32.

    Yan KP, Dolle P, Mark M, Lerouge T, Wendling O, Chambon P, et al. Molecular cloning, genomic structure, and expression analysis of the mouse transcriptional intermediary factor 1 gamma gene. Gene. 2004;334:3-13.

    Not in our library10.1016/j.gene.2004.02.056

33. 33.

    Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum. 2007;56:3132-7.

    Not in our library10.1002/art.22862

34. 34.

    Rosendorff A, Sakakibara S, Lu S, Kieff E, Xuan Y, et al. NXP-2 association with SUMO-2 depends on lysines required for transcriptional repression. Proc Natl Acad Sci U S A. 2006;103:5308-13.

    Not in our library10.1073/pnas.0601066103

Cited by papers we hold 4

• Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis · 2018
  Not checked
• Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians? · 2018
  No notice
• Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort · 2017
  No notice
• Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset · 2014
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.